Clinical trials: Renal Insufficiency, Acute
Multiple Myeloma
A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg
1. Planned enrollment period One year (The planned number of patients to be enrolled is set to 400 patients.) Since all patients who are prescribed with Pomalyst are registered in RevMate®, enrollment using the Registration Form…
- Trial name
- NCT02921828
- Where
- 2 sites in United States, Japan
- Volunteers
- 1,149 people
- Sponsor
- Celgene
Cardiac Surgery
QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery
This trial is designed to evaluate QPI-1002 versus placebo for the prevention of Major Adverse Kidney Events (MAKE) in subjects at high risk for acute kidney injury following cardiac surgery.
- Trial name
- NCT03510897
- Testing
- teprasiran
- Where
- 104 sites in United States, Australia and 9 more
- Volunteers
- 1,043 people
- Sponsor
- Quark Pharmaceuticals
Acute Kidney Injury
Trial for the Early Identification of Acute Kidney Injury
Previse is a novel, software-based clinical decision support (CDS) system that predicts acute kidney injury (AKI). Previse uses machine learning methods and information drawn from the electronic health record (EHR) to identify…
- Trial name
- NCT04200950
- Testing
- Previse
- Volunteers
- healthy volunteers welcome
- Sponsor
- Dascena
Renal Failure, Acute Renal Failure
Premarket Clinical Safety Assessment of the ELISIO™-HX
The primary safety objective of this study is to evaluate the safety of the use of the high-permeability hemodialyzer series ELISIO™-HX, by showing that the pre-dialysis albumin levels are not affected using the investigational…
- Conditions
- Renal Failure, Acute Renal Failure, Chronic Renal Failure, Chronic Kidney Diseases
- Trial name
- NCT07058909
- Testing
- ELISIO™-HX Dialyzer
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Nipro Medical Corporation
Renal Insufficiency, Acute Kidney Injury
Renal Assist Device (RAD) for Patients With Renal Insufficiency Undergoing Cardiac Surgery
The study is a prospective, non-randomized early feasibility study intended to evaluate the safety and performance of the JuxtaFlow System (also known as the JuxtaFlow Renal Assist Device (RAD)) in participants with pre-existing…
- Trial name
- BIPASS-AKI (NCT05990660)
- Testing
- JuxtaFlow System
- Where
- 3 sites in Poland, Serbia
- Volunteers
- 10 people
- Sponsor
- 3ive Labs
Acute Renal Failure (ARF), Acute Tubular Necrosis
Use of QRX3 for Acute Tubular Necrosis Type of Renal Failure in Hospitalized Patients ( QRX-3 in ARF)
Use of QRX-3 in hospitalized patients with pediatric and adult patients with acute tubular necrosis renal failure
- Trial name
- QRX3 in ARF (NCT07161843)
- Testing
- QRX-3
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Ebima Clifford Okundaye
Diabetes Mellitus, Type 2
Risk of Acute Kidney Injury Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments
The purpose of this study is to compare the incidence of hospitalization for acute kidney injury among patients with type 2 diabetes who are new initiators of Saxagliptin and those who are new initiators of other oral…
- Trial name
- NCT01377935
- Volunteers
- 113,505 people
- Sponsor
- AstraZeneca
Coronary Artery Disease
The Use of Aging Biomarkers to Predict Adverse Outcomes After Cardiac Surgery
Cardiac surgery associated acute kidney injury (CSA-AKI) has been recognized as the second most common cause of hospital acquired AKI.
- Trial name
- NCT02496234
- Where
- United States
- Volunteers
- 186 people
- Sponsor
- Sapere Bio
Acute Renal Failure
Open-Label Study To Evaluate the Safety and Efficacy of the Renal Assist Device In Patients With Acute Renal Failure
Although conventional hemodialysis removes waste products and corrects fluid imbalance, it does not replace critical absorptive, metabolic, endocrine, and immunologic functions performed by healthy renal tubule cells.
- Trial name
- NCT00511407
- Testing
- Renal tubule assist device
- Where
- 13 sites in United States
- Volunteers
- 58 people
- Sponsor
- RenaMed Biologics
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment
This is a Phase 1b, multicenter, open-label, PK, and safety study of multiple oral doses of oral decitabine and cedazuridine (formerly known as ASTX727) as a fixed-dose combination of decitabine 35 milligrams (mg) and…
- Trial name
- NCT04953897
- Testing
- ASTX727
- Where
- 21 sites in United States, Armenia and 6 more
- Volunteers
- 18 people
- Sponsor
- Taiho Oncology, Inc.
Radiographic Contrast Agent Nephropathy
Contrast Media Reduction and Removal in Patients With Chronic Kidney Disease (CKD) (PRESERV)
The purpose of this clinical trial is to demonstrate the efficacy and safety of the Osprey Medical CINCOR™ Contrast Removal System.
- Trial name
- NCT01168024
- Testing
- CINCOR™ System and contrast conservation unit (CCS-1), Standard of Care plus peri-procedural hydration
- Where
- 21 sites in United States, Germany
- Volunteers
- 16 people
- Sponsor
- Osprey Medical, Inc
Acute Kidney Injury
A Sample Collection Study to Validate the NEPHROCLEAR™ CCL14 Test
The objective of this sample collection study is to collect urine samples to validate the NEPHROCLEAR™ CCL14 Test in patients with KDIGO stage 2 or 3 AKI.
- Trial name
- NCT04785391
- Testing
- Urine collection for NEPHROCLEAR CCL14 Test
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Astute Medical, Inc.
AKI - Acute Kidney Injury, Cardiac Surgery Associated - Acute Kidney Injury
Post-Marketing Study to Assess the Safety & Efficacy of RenalGuard® Therapy for Prevention CSA-AKI
The goal of this clinical trial is to assess the effect of RenalGuard Therapy in reducing the rates of Acute Kidney Injury (AKI) within 72 hours after cardiac surgery in patients at risk of developing Cardiac Surgery Associated…
- Trial name
- KIDNEY-II (NCT06811805)
- Testing
- RenalGuard Therapy, Standard of Care (SOC)
- Where
- 8 sites in Belgium, Germany and 3 more
- Volunteers
- 300 people
- Sponsor
- CardioRenal Systems, Inc.
Cardiac Surgery, Coronary Artery Bypass
An Trial of Two Dosing Regimens of AP214 for the Prevention of Kidney Injury in Patients Undergoing Cardiac Surgery
This study investigates the effect of two dose-levels of AP214 on the prevention of (acute) kidney injury after cardiac surgery.
- Conditions
- Cardiac Surgery, Coronary Artery Bypass, Aortic Aneurysm, Valve Surgery
- Trial name
- NCT01256372
- Testing
- AP214
- Where
- Denmark
- Volunteers
- 77 people
- Sponsor
- Action Pharma A/S
Acute Kidney Injury, Septic Shock
Targeting Abdominal Perfusion Pressure in Septic Shock
A randomized control trial among patients with septic shock, studying the incidence, progression and recovery of AKI.
- Conditions
- Acute Kidney Injury, Septic Shock, Resuscitations
- Trial name
- MAP-APP (NCT03582046)
- Testing
- Abdominal Perfusion Pressure (APP), Mean Arterial Pressure (MAP)
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Potrero Medical
Acute Kidney Injury
VIDAS Nephroclear (NCL) CCL14 - Sample Stability
This VIDAS® NEPHROCLEAR™ CCL14 (VIDAS® NCL™ CCL14) Sample Stability clinical trial is a multicenter, prospective, and qualitative study.
- Trial name
- NCT05271617
- Testing
- VIDAS® NEPHROCLEAR™ CCL14
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- BioMérieux
Critical Illness, Acute Kidney Injury
Collective Accuryn Physiologic Signals and Signatures
The CAPSS Study is a retrospective and prospective, multi-center, single-arm post-market data collection study with an FDA cleared device.
- Conditions
- Critical Illness, Acute Kidney Injury, Sepsis, Septic Shock
- Trial name
- CAPSS (NCT03817281)
- Testing
- Accuryn Monitoring System
- Where
- United States
- Sponsor
- Potrero Medical
Acute Respiratory Distress Syndrome, Acute Kidney Injury
A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+
PrismaLung+ is a sterile, single-use medical device aimed at performing partial removal of carbon dioxide (CO2) from the patient's venous blood via diffusion through a membrane.
- Trial name
- SPARE (NCT07326215)
- Testing
- PrismaLung+, Invasive Mechanical Ventilation
- Where
- 10 sites in China
- Volunteers
- 99 people
- Sponsor
- Vantive Health LLC
Acute Kidney Injury
A Study of the PK Interaction of CXA-10 With Pravastatin and Vytorin® in Healthy Males
This is an exploratory study in a small, well controlled group of healthy subjects to explore the effect of CXA-10 on pravastatin and Vytorin® (combination of simvastatin and ezetimibe).
- Trial name
- DDI (NCT02547402)
- Testing
- CXA-10, pravastatin, Vytorin® (combination of simvastatin and ezetimibe)
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Complexa, Inc.
Cardiothoracic Surgery, Vascular Surgery
A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Surgery
This study will evaluate the safety and efficacy of ABT-719 in patients undergoing high risk major surgery.
- Trial name
- NCT01897519
- Testing
- ABT-719
- Where
- 23 sites in United States, Denmark
- Volunteers
- 56 people
- Sponsor
- AbbVie